BChE-IN-4 is a highly potent inhibitor of the enzyme butyrylcholinesterase, capable of crossing the blood-brain barrier. It effectively reduces learning and memory impairments resulting from a deficiency in cholinergic activity in a mouse model. BChE-IN-4 holds promise for further investigation in the field of Alzheimer's disease research [1].

BChE-IN-4 (compound 1) (10, 20, 30 mg/kg) attenuates learning and memory deficits caused by cholinergic deficit in AD mouse model [1]. BChE-IN-4 (30 mg/kg) dose not induce adverse motor effects in vivo [1]. Animal Model: Adult male Albino Swiss CD-1 mice (Scopolamine-induced memory-impaired CD-1 mice) [1] Dosage: 10, 20, 30 mg/kg Administration: I.p. Result: Significantly prolonged the step-through latencies in memory impaired mice. Animal Model: 18-22 g, C57BL/6J mice [1] Dosage: 30 mg/kg Administration: I.p. Result: Did not enhance learning abilities and working memory in the acquisition phase or the short-term memory retrieval on day 5, but did significantly improve long-term memory retrieval, as observed on day 12 of the BM ( Barnes maze) task. Animal Model: Mice [1] Dosage: 30 mg/kg (suspended in 1% Tween 80) Administration: I.p Result: Neither altered the number of light-beam interruptions in the locomotor activity test nor induced any motor deficits at 6, 18 and 24 rpm in the rotarod test.